2. Search Result
Search Result
Results for "

duct

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

10

Peptides

2

MCE Kits

1

Inhibitory Antibodies

7

Natural
Products

3

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1427
    Glycodeoxycholate Sodium
    2 Publications Verification

    Sodium glycyldeoxycholate

    		 Endogenous Metabolite Metabolic Disease
    Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .
    Glycodeoxycholate Sodium
  • HY-109120
    Odevixibat
    3 Publications Verification

    A4250

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat
  • HY-101194
    Tin protoporphyrin IX dichloride
    15+ Cited Publications

    Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX

    		 Reactive Oxygen Species Cancer
    Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model .
    Tin protoporphyrin IX dichloride
  • HY-B1557
    Betazole
    1 Publications Verification

    Ametazole

    		 Histamine Receptor Metabolic Disease
    Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
    Betazole
  • HY-169113
    EPZ032597

    		Histone Methyltransferase Cancer
    EPZ032597 is a selective and noncompetitive SMYD2 inhibitor with an IC50 value of 16 nM. EPZ032597 is promising for research of pancreatic ductal adenocarcinoma .
    EPZ032597
  • HY-147838
    Nampt-IN-9

    		NAMPT Cancer
    Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .
    Nampt-IN-9
  • HY-116212
    JCP-170

    		MAGL Cancer
    JCP-170, a substituted chloroisocoumarin, is an ABHD6 inhibitor. JCP-170 robustly and reproducibly inhibits metastatic seeding of the murine cell line 0688M and both human pancreatic ductal adenocarcinoma (PDAC) cell lines .
    JCP-170
  • HY-P1535
    Secretin, porcine

    Porcine secretin acetate

    		 Secretin Receptor Inflammation/Immunology
    Secretin, porcine (Porcine secretin acetate) is a 27-amino acid peptide, acting on pancreatic acinar cells and ductal epithelial cells stimulating the production of bicarbonate rich fluid.
    Secretin, porcine
  • HY-P1535A
    Secretin, porcine TFA

    Porcine secretin TFA

    		 Secretin Receptor Inflammation/Immunology
    Secretin, porcine TFA (Porcine secretin TFA) is a 27-amino acid peptide, acting on pancreatic acinar cells and ductal epithelial cells stimulating the production of bicarbonate rich fluid .
    Secretin, porcine TFA
  • HY-109120S
    Odevixibat-d5

    A4250-d5

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-d5
  • HY-109120S1
    Odevixibat-13C6

    A4250-13C6

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat- 13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-13C6
  • HY-B1557A
    Betazole dihydrochloride

    Ametazole dihydrochloride

    		 Histamine Receptor Metabolic Disease
    Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .
    Betazole dihydrochloride
  • HY-156027
    SIRT6-IN-3

    		Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK Neurological Disease Inflammation/Immunology Endocrinology Cancer
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .
    SIRT6-IN-3
  • HY-161346
    EBET-1055

    		PROTACs Epigenetic Reader Domain Cancer
    EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .
    EBET-1055
  • HY-19694
    BRD7552

    		Insulin Receptor Endocrinology
    BRD7552, a potent PDX1 transcription factor inducer, upregulates PDX1 expression in both primary human islets and ductal cells, and induces epigenetic changes in the PDX1 promoter consistent with transcriptional activation. BRD7552 increases insulin expression. PDX1 is a key transcription factor involved in pancreas development and β cell function .
    BRD7552
  • HY-B1557R
    Betazole (Standard)

    		Histamine Receptor Metabolic Disease
    Betazole (Standard) is the analytical standard of Betazole. This product is intended for research and analytical applications. Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
    Betazole (Standard)
  • HY-155222
    TW9

    		Epigenetic Reader Domain HDAC Cancer
    TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC50 of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026) .
    TW9
  • HY-148808
    Zelasudil

    RXC007

    		 ROCK Cancer
    Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
    Zelasudil
  • HY-122723
    GOT1 inhibitor-1
    2 Publications Verification

    		 Reactive Oxygen Species Cancer
    GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC50 of 8.2 uM. GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC) .
    GOT1 inhibitor-1
  • HY-P99379
    Nidanilimab (Nadunolimab)

    CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)

    		 Interleukin Related Cancer
    Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
    Nidanilimab (Nadunolimab)
  • HY-172177
    ROCK/HDAC-IN-2

    		Apoptosis HDAC ROCK Cancer
    ROCK/HDAC-IN-2 (Compound C-9) is a ROCK/HDAC inhibitor, with IC50 values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, ROCK1, and ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .
    ROCK/HDAC-IN-2
  • HY-100498
    GSK2256098
    5 Publications Verification

    		 FAK Apoptosis Cancer
    GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    GSK2256098
  • HY-148260
    KRAS G12D inhibitor 16

    		Ras Cancer
    KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .
    KRAS G12D inhibitor 16
  • HY-A0190
    Ceruletide
    Maximum Cited Publications
    91 Publications Verification

    Caerulein; Cerulein; FI-6934

    		 Cholecystokinin Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
    Ceruletide
  • HY-158722
    Caerulein acetate

    		Cholecystokinin Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
    Caerulein acetate
  • HY-160850
    C18 Ceramide-1-phosphate (d18:1/18:0) ammonium salt

    		Endogenous Metabolite Endocrinology
    C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) is a specific type of long-chain molecule found in murine skin . C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 µM. C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .
    C18 Ceramide-1-phosphate (d18:1/18:0) ammonium salt
  • HY-N10810
    Gentioflavin

    		Others Others
    Gentioflavin is an alkaloid. Gentioflavin can be isolated from the root of Long Dan (G. scabra), a traditional substance against liver or bile duct disease .
    Gentioflavin
  • HY-136750
    Z-LLY-FMK

    Calpain Inhibitor IV

    		 Apoptosis Proteasome Cancer
    Z-LLY-FMK (Calpain Inhibitor IV) is a calpain inhibitor, involved in apoptosis of many cell systems. Z-LLY-FMK inhibits the intestine apoptosis after common bile duct ligation .
    Z-LLY-FMK
  • HY-A0190R
    Ceruletide (Standard)

    		Cholecystokinin Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Ceruletide (Standard) is the analytical standard of Ceruletide. This product is intended for research and analytical applications. Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
    Ceruletide (Standard)
  • HY-120396
    LY 293284

    		5-HT Receptor Neurological Disease
    LY 293284 is a potent and selective 5-HT1A receptor agonist. LY 293284 results in a significant drop in core temperature and consumes more food in cholestasis rat induced by bile duct resection .
    LY 293284
  • HY-B0149S3
    Tranexamic acid-13C2,15N

    Cyclocapron-13C2,15N

    		 Isotope-Labeled Compounds Inflammation/Immunology
    Tranexamic acid- 13C2, 15N (Cyclocapron- 13C2, 15N) is the 13C2 and 15N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .
    Tranexamic acid-13C2,15N
  • HY-N6237
    Aspulvinone O

    		Reactive Oxygen Species Infection
    Aspulvinone O is a natural inhibitor of aspartate transaminase 1 (GOT1). GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 may serve as an important target in PDAC. Aspulvinone O suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism .
    Aspulvinone O
  • HY-160045
    AP1153 aptamer sodium

    		Cholecystokinin Receptor Cancer
    AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .
    AP1153 aptamer sodium
  • HY-139562
    BMS-986318

    		FXR Metabolic Disease
    BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis .
    BMS-986318
  • HY-137561A
    Bexotegrast hydrochloride

    PLN-74809 hydrochloride

    		 Integrin Inflammation/Immunology
    Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
    Bexotegrast hydrochloride
  • HY-W747072
    3-Sulfo-taurocholic Acid Disodium Salt

    3-Sulfocholyl Taurine; TCA3S

    		 Drug Metabolite Metabolic Disease
    3-Sulfo-taurocholic Acid Disodium Salt (3-Sulfocholyl Taurine; TCA3S) is a metabolite of the conjugated bile acid taurocholic acid. Plasma levels of 3-Sulfo-taurocholic Acid Disodium Salt are elevated in wild-type and Sortilin 1 (Sort1) knockout mice at 6 hours following bile duct ligation (BDL) and are further elevated in Sort1 knockout mice at 24 hours post-BDL.
    3-Sulfo-taurocholic Acid Disodium Salt
  • HY-N1427R
    Glycodeoxycholate (Sodium) (Standard)

    		Endogenous Metabolite Metabolic Disease
    Glycodeoxycholate (Sodium) (Standard)
  • HY-15211
    MRK 003

    		γ-secretase Apoptosis Neurological Disease Cancer
    MRK 003 is a potent, selective and orally active γ-secretase inhibitor. MRK 003 reduce brain Aβ production in vivo. MRK 003 induces caspase-dependent apoptosis and inhibits tumor cell proliferation in vivo and in vitro .
    MRK 003
  • HY-W288951
    FMP-API-1

    		PKA Metabolic Disease
    FMP-API-1 is an A-kinase anchoring protein (AKAP)-PKA interaction inhibitor. FMP-API-1 binds to the allosteric site of PKA R subunits and increases the activity of PKA and AQP2 in PKA-knockout cell lines of renal cortical collecting ducts (mpkCCD cells). FMP-API-1 has the potential for the study of nephrogenic diabetes insipidus (NDI) .
    FMP-API-1
  • HY-165245
    SBI-183

    		Transmembrane Glycoprotein Cancer
    SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
    SBI-183
  • HY-P5291
    CPF-7

    Caerulein precursor fragment

    		 Insulin Receptor Metabolic Disease
    CPF-7 (Caerulein precursor fragment) is an insulin-releasing peptide that stimulates the release of insulin. CPF-7 can induce epithelial-mesenchymal transition by upregulating Snai1 expression in PANC-1 ductal cells. CPF-7 also induces exocrine plasticity by upregulating Ngn3 expression. CPF-7 can be used in the research of type 2 diabetes .
    CPF-7
  • HY-N13944
    Argyrin F

    		Apoptosis Cancer
    Argyrin F a cyclic peptide with antitumoral activities. Argyrin F inhibits cell proliferation, migration, invasion and colony formation by partial induction of apoptosis and epithelial-mesenchymal transition (EMT). Argyrin F stabilizes p27 kip, up-regulated p21 waf1/cip1 and depletes COX2. Argyrin F can be used for the study of pancreatic ductal adenocarcinoma (PDAC) .
    Argyrin F
  • HY-147008
    XP-524

    		Epigenetic Reader Domain Cancer
    XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .
    XP-524
  • HY-161767
    JWJ-01-306

    		Molecular Glues Cancer
    JWJ-01-306 is a molecular glue that targets the C2H2 zinc finger transcription factor ZBTB11. JWJ-01-306 degrades ZBTB11, reduces the oxidative phosphorylation (OXPHOS) and tricarboxylic acid (TCA) cycle, and inhibits the proliferation of KAS-resistant PDAC cells. JWJ-01-306 exhibits good pharmacokinetic characteristics in mouse model .
    JWJ-01-306
  • HY-100669
    Mycro 3
    5 Publications Verification

    		 c-Myc Autophagy Cancer
    Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .
    Mycro 3
  • HY-164202
    ORM-5029

    		Antibody-Drug Conjugates (ADCs) Cancer
    ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 can be used for study of cancer .
    ORM-5029
  • HY-P3203
    DSTYSLSSTLTLSK

    		Biochemical Assay Reagents Inflammation/Immunology
    DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
    DSTYSLSSTLTLSK
  • HY-169004
    CBT-295

    		TGF-beta/Smad Interleukin Related Neurological Disease Inflammation/Immunology
    CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .
    CBT-295
  • HY-18652A
    Avutometinib potassium

    Ro 5126766 potassium; CH5126766 potassium

    		 Raf MEK Cancer
    Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .
    Avutometinib potassium
  • HY-168718
    FAK-IN-22

    		FAK JAK Aurora Kinase PI3K Akt Apoptosis Cancer
    FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway .
    FAK-IN-22

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: